PMID- 31128298
OWN - NLM
STAT- MEDLINE
DCOM- 20200504
LR  - 20211204
IS  - 1096-3650 (Electronic)
IS  - 1044-579X (Linking)
VI  - 59
DP  - 2019 Dec
TI  - Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and 
      therapeutic significance.
PG  - 147-160
LID - S1044-579X(18)30177-9 [pii]
LID - 10.1016/j.semcancer.2019.05.012 [doi]
AB  - Ovarian cancer (OC) is a lethal gynecological cancer. The phosphatidylinositol 
      3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway plays 
      an important role in the regulation of cell survival, growth, and proliferation. 
      Irregularities in the major components of the PI3K/AKT/mTOR signaling pathway are 
      common in human cancers. Despite the availability of strong pre-clinical and 
      clinical data of PI3K/AKT/mTOR pathway inhibitors in OC, there is no FDA approved 
      inhibitor available for the treatment of OC. Here, we outline the importance of 
      PI3K/AKT/mTOR signaling pathway in OC tumorigenesis, proliferation and 
      progression, and pre-clinical and clinical experience with several PI3K/AKT/mTOR 
      pathway inhibitors in OC.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Ediriweera, Meran Keshawa
AU  - Ediriweera MK
AD  - Institute of Biochemistry, Molecular Biology and Biotechnology, University of 
      Colombo, 90, Cumaratunga Munidasa Mawatha, Colombo 03, Sri Lanka. Electronic 
      address: mk.ediriweera@gmail.com.
FAU - Tennekoon, Kamani Hemamala
AU  - Tennekoon KH
AD  - Institute of Biochemistry, Molecular Biology and Biotechnology, University of 
      Colombo, 90, Cumaratunga Munidasa Mawatha, Colombo 03, Sri Lanka.
FAU - Samarakoon, Sameera Ranganath
AU  - Samarakoon SR
AD  - Institute of Biochemistry, Molecular Biology and Biotechnology, University of 
      Colombo, 90, Cumaratunga Munidasa Mawatha, Colombo 03, Sri Lanka.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190522
PL  - England
TA  - Semin Cancer Biol
JT  - Seminars in cancer biology
JID - 9010218
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Epigenesis, Genetic
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Ovarian Neoplasms/drug therapy/etiology/*metabolism/pathology
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors/pharmacology/therapeutic use
MH  - Protein Kinase Inhibitors/pharmacology/therapeutic use
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - *Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*metabolism
OTO - NOTNLM
OT  - AKT
OT  - Ovarian cancer
OT  - PI3K
OT  - Pathway
OT  - mTOR
EDAT- 2019/05/28 06:00
MHDA- 2020/05/06 06:00
CRDT- 2019/05/26 06:00
PHST- 2018/11/30 00:00 [received]
PHST- 2019/04/28 00:00 [revised]
PHST- 2019/05/21 00:00 [accepted]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2020/05/06 06:00 [medline]
PHST- 2019/05/26 06:00 [entrez]
AID - S1044-579X(18)30177-9 [pii]
AID - 10.1016/j.semcancer.2019.05.012 [doi]
PST - ppublish
SO  - Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. 
      Epub 2019 May 22.